X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Wednesday, March 14, 2018, at 8:00 a.m. Eastern time.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing
novel therapeutics designed to improve immune cell trafficking to treat
cancer and rare diseases. The Company’s oral small molecule drug
candidates inhibit the CXCR4 receptor, a pathway which plays a central
role in immune surveillance. X4’s most advanced product candidate,
X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a
rare genetic, primary immunodeficiency disease. X4P-001-IO is currently
under investigation in multiple Phase 1/2 studies in refractory clear
cell renal cell carcinoma (ccRCC) and melanoma. X4 was founded and is
led by a team with deep product development and commercialization
expertise, including several former members of the Genzyme leadership
team, and is located in Cambridge, MA. For more information please visit X4pharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005148/en/
The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com
